

## EC-TPH (Epirubicin and Cyclophosphamide then Docetaxel, Pertuzumab and Trastuzumab)

### Indication

Neo-adjuvant treatment for HER2 positive, locally advanced, inflammatory or early stage breast cancer at high risk of recurrence.

(NICE TA424)

Adjuvant treatment for HER2 positive, early stage breast cancer with lymph node positive disease.

(NICE TA569)

### ICD-10 codes

Codes with a prefix C50.

### Regimen details

#### Cycles 1-3\*

Day	Drug	Dose	Route
1	Epirubicin*	100mg/m <sup>2</sup>	IV bolus
1	Cyclophosphamide	500mg/m <sup>2</sup>	IV bolus

\*lower doses of 60mg/m<sup>2</sup> or 75mg/m<sup>2</sup> may be used for patients with significant co-morbidity

Patients may receive treatment with either IV Pertuzumab and IV Trastuzumab or the combined SC Pertuzumab/Trastuzumab preparation, Phesgo.

#### IV Pertuzumab/Trastuzumab

#### Cycle 4

Day	Drug	Dose	Route
1	Pertuzumab	840mg	IV infusion
1	Trastuzumab	8mg/kg	IV infusion
1	Docetaxel	75mg/m <sup>2</sup>	IV infusion

Due to the potential for hypersensitivity reactions, for this cycle pertuzumab may be administered on day 1 and trastuzumab and docetaxel on day 2.

#### Cycles 5-7:

Day	Drug	Dose	Route
1	Pertuzumab	420mg	IV infusion
1	Trastuzumab	6mg/kg	IV infusion
1	Docetaxel	*75mg/m <sup>2</sup>	IV infusion

\*Docetaxel may be escalated to 100mg/m<sup>2</sup> for subsequent cycles if the initial dose is tolerated, at the consultants' discretion.

### Cycles 8-21

Day	Drug	Dose	Route
1	Pertuzumab	420mg	IV infusion
1	Trastuzumab	6mg/kg	IV infusion

If the dosing interval is > 4 weeks for trastuzumab or ≥ 6 weeks for pertuzumab, a loading dose will be required.

### SC Pertuzumab/Trastuzumab

#### Cycle 4

Day	Drug	Dose	Route
1	Phesgo (Pertuzumab 1200mg/Trastuzumab 600mg)	1200mg/600mg	SC injection
1	Docetaxel	75mg/m <sup>2</sup>	IV infusion

#### Cycles 5-7:

Day	Drug	Dose	Route
1	Phesgo (Pertuzumab 600mg/Trastuzumab 600mg)	600mg/600mg	SC injection
1	Docetaxel	*75mg/m <sup>2</sup>	IV infusion

\*Docetaxel may be escalated to 100mg/m<sup>2</sup> for subsequent cycles if the initial dose is tolerated, at the consultants' discretion.

#### Cycles 8-21

Day	Drug	Dose	Route
1	Phesgo (Pertuzumab 600mg/Trastuzumab 600mg)	600mg/600mg	SC injection

If the dosing interval is ≥ 6 weeks for Phesgo, a loading dose will be required.

### Cycle frequency

21 days

### Number of cycles

Maximum of 7 cycles (3 x EC followed by 3-4 x TPH).

Pertuzumab and trastuzumab should be continued to complete 1 year of treatment (maximum 18 cycles in total).

### Administration

#### Cycles 1-3:

Epirubicin and cyclophosphamide are administered by slow IV bolus into the arm of a fast running drip of sodium chloride 0.9%. Cyclophosphamide may also be given as an IV infusion in 250-500mL sodium chloride 0.9% over 30 minutes.

#### Cycles 4-7:

#### IV Pertuzumab/Trastuzumab

IV Pertuzumab and trastuzumab may be administered in either order but the docetaxel should be administered last.

IV Pertuzumab is administered in 250mL sodium chloride 0.9% over 60 minutes (cycle 4) followed by a 60 minute observation period (before next drug administration). For cycle 5 onwards (providing pertuzumab is well tolerated) IV pertuzumab may be administered over 30 minutes followed by a 60 minute observation period.

IV Trastuzumab is administered in 250mL sodium chloride 0.9% over 90 minutes (cycle 4). The patient should be observed for 6 hours after the start of the infusion for symptoms of infusion related reactions (e.g. fever, chills). For cycle 5 onwards, (providing trastuzumab well tolerated) IV trastuzumab may be given over 30 minutes. Patients should be observed for 2 hours after the start of the infusion for symptoms of infusion related reactions.

It may not be necessary to stop treatment for minor hypersensitivity reactions e.g. flushing, localised rash but infusions must be stopped for major reactions, e.g. hypotension, dyspnoea, angioedema or generalised urticaria.

### **Subcutaneous Pertuzumab/Trastuzumab (Phesgo)**

Phesgo should always be administered prior to Docetaxel administration.

Phesgo loading dose (1200mg Pertuzumab/600mg Trastuzumab) is administered in a volume of 15mL by subcutaneous injection over approximately 8 minutes. Phesgo maintenance dose (600mg Pertuzumab/600mg Trastuzumab) is administered in a volume of 10mL by subcutaneous injection over approximately 5 minutes. The injection site should be alternated between the left and right thigh only. New injections should be given at least 2.5 cm from the previous site on healthy skin and never into areas where the skin is red, bruised, tender, or hard. The dose should not be split between two syringes or between two sites of administration.

Patients should be observed for 30 minutes after completion of the Phesgo loading dose and 15 minutes after completion of a Phesgo maintenance dose for injection-related reactions.

### **Docetaxel**

Docetaxel is administered as an IV infusion in 250mL or 500mL (concentration dependent) PVC free sodium chloride 0.9% over 60 minutes.

Patients should be observed closely for hypersensitivity reactions, particularly during the first and second infusions. Hypersensitivity reactions may occur within a few minutes following the initiation of the infusion of docetaxel and therefore facilities for the treatment of hypotension and bronchospasm must be available.

If hypersensitivity reactions occur, minor symptoms such as flushing or localised cutaneous reactions do not require discontinuation of therapy. The infusion may be temporarily interrupted and when symptoms improve re-started at a slower infusion rate. Severe reactions, such as hypotension, bronchospasm or generalised rash/erythema require immediate discontinuation of docetaxel and appropriate therapy.

Patients who have developed severe hypersensitivity reactions should not be re-challenged with docetaxel, unless following a risk assessed desensitisation protocol.

### **Cycles 8-21:**

Pertuzumab and trastuzumab are administered as above.

### **Pre-medication**

EC cycles: none usually required

TPH cycles: Dexamethasone 8 mg BD (morning and lunchtime) for 3 days starting 24 hours prior to chemotherapy. (Note: Patients must receive 3 doses of dexamethasone prior to treatment).

In the case where 3 doses have not been taken, dexamethasone 16-20mg IV should be administered 30-60 minutes prior to chemotherapy and the remaining 3 oral doses should be taken as normal.

### Emetogenicity

EC cycles: moderate – moderate - high emetic potential

TPH cycles: moderate-low emetic potential

### Additional supportive medication

Primary G-CSF prophylaxis as per local policy

Mouthwashes as per local policy

H<sub>2</sub> antagonist or proton-pump inhibitor if required

Loperamide if required (particularly for TPH cycles)

Scalp cooling may be offered.

### Extravasation

Epirubicin is a vesicant (Group 5)

Cyclophosphamide, pertuzumab and trastuzumab are neutral (Group 1)

Docetaxel is an exfoliant (Group 4)

### Investigations – pre first cycle

Investigation	Validity period (or as per local policy)
FBC	14 days
U+E (including creatinine)	14 days
LFTs	14 days
Echocardiogram	Baseline

### Investigations – pre cycles 2-7

Investigation	Validity period (or as per local policy)
FBC	96 hours
U+E (including creatinine)	7 days
LFTs	7 days
Echocardiogram	Pre cycle 4 and cycle 6 or according to local practice.

### Investigations – pre HER-2 directed maintenance cycles 8-21

Investigation	Validity period (or as per local policy)
FBC	3 monthly
U+E (including creatinine)	3 monthly
LFTs	3 monthly
Echocardiogram	Every 3-4 months or according to local practice

### Standard limits for administration to go ahead

If blood results not within range, authorisation to administer **must** be given by prescriber/ consultant

Investigation	Limit
Neutrophils	≥ 1.0 x 10 <sup>9</sup> /L
Platelets	≥ 100 x 10 <sup>9</sup> /L
Creatinine Clearance (CrCl)	> 20 mL/min
Bilirubin	≤ 1.0 ULN*
AST/ALT	≤ 1.5 x ULN*
Alkaline Phosphatase	≤ 2.5 x ULN
Echocardiogram (cycle 4 onwards) – LVEF	≥ Lower Limit of Normal for the institution (LNN)

\*See table below for standard limits to go ahead for EC cycles

## Dose modifications

- Haematological toxicity**

If neutrophils  $<1.0 \times 10^9/L$  and/or platelets  $<100 \times 10^9/L$  delay 1 week or until recovery.

If febrile neutropenia or neutrophils  $<0.5 \times 10^9/L$  for more than 1 week consider reducing doses of all cytotoxic drugs to 80% (except trastuzumab and pertuzumab) for future cycles.

Trastuzumab and pertuzumab may continue during periods of chemotherapy induced myelosuppression.

- Renal impairment**

CrCl (mL/min)	Cyclophosphamide dose
> 20	100%
10-20	75%
<10	50%

Epirubicin: There is no data available in severe renal impairment. Consider dose reduction if CrCl  $<10\text{mL/min}$  (consultant decision).

Docetaxel: consider dose reduction if CrCl  $<10\text{mL/min}$  (consultant decision).

Trastuzumab: No dose modification for renal function is required.

Pertuzumab: No dose modification is required for mild or moderate impairment. No dose reductions can be made in severe renal impairment as there is limited data available.

- Hepatic impairment**

### EC cycles:

Bilirubin (x ULN)		AST/ALT (x ULN)		Alkaline phosphatase (xULN)	Epirubicin dose
< 1.5	and	$\leq 2.0$	and	$\leq 2.5$	100%
1.5 - < 3	or	> 2.0 -3.5	or	> 2.5 - <5	50%
$\geq 3$ - 5	or	> 3.5	and	5-10	25%
> 5			or	> 10	Omit

Cyclophosphamide is not recommended if bilirubin  $> 1.5 \times \text{ULN}$  or AST/ALT  $> 3 \times \text{ULN}$  (consultant decision).

### TPH cycles:

AST/ALT (x ULN)		Alkaline phosphatase (x ULN)	Docetaxel dose
$\leq 1.5$	and	$< 2.5$	100%
> 1.5 – 3.5	or	$\geq 2.5$ - 6	75%
> 3.5	or	$\geq 6$	60% or discontinue - discuss with consultant

If AST/ALT is 1.5-2.5 x ULN and alkaline phosphatase is  $<2.5 \times \text{ULN}$  the maximum recommended dose of docetaxel is  $75 \text{ mg/m}^2$

If bilirubin  $> 1.0 \times \text{ULN}$  withhold dose (or consultant decision to treat)

No dose modification is required for trastuzumab.

Pertuzumab has not been studied in hepatic impairment; no dose recommendations can be made

- **Other toxicities**

**EC cycles:**

For grade 3 or 4 mucositis/stomatitis – delay until resolved to  $\leq$  grade 1 and reduce dose of fluorouracil and epirubicin to 80% dose.

Any other grade 3 or 4 toxicity- discuss with consultant.

**TPH cycles:**

Toxicity	Definition	Docetaxel dose
Peripheral neuropathy	Grade 2	75%
	Grade 3 or 4	Discuss with consultant
Diarrhoea*	Grade 3 or 4	1 <sup>st</sup> occurrence – 75%
		2 <sup>nd</sup> occurrence – 60%
Stomatitis	Grade 3 or 4	1 <sup>st</sup> occurrence – 75%
		2 <sup>nd</sup> occurrence – 60%

\*Pertuzumab may cause severe diarrhoea. If severe diarrhoea an anti-diarrhoeal treatment should be instituted and interruption of the treatment with pertuzumab should be considered if no improvement of the condition is achieved. When the diarrhoea is under control the treatment with pertuzumab may be reinstated.

**Left ventricular dysfunction**

LVEF must be above LLN for treatment to go ahead. The summary of product characteristics (SPC) for pertuzumab states that cardiac monitoring is required every 2 cycles for the first 4 cycles. For cycle 5 onwards cardiac monitoring should be every 3 – 4 months whilst on trastuzumab/pertuzumab with additional monitoring after completion according to local practice or SPC.

LVEF	Trastuzumab/Pertuzumab
> LLN	Continue
40-LLN and decrease < 10% from baseline <b>and</b> asymptomatic	Continue. If BP and renal function adequate start an ACE inhibitor (eg ramipril 2.5mg) and consider a beta blocker (eg bisoprolol 2.5mg). Repeat LVEF within 3 weeks
40-LNN and decrease $\geq$ 10% from baseline <b>and</b> asymptomatic	Withhold. If BP and renal function adequate start an ACE inhibitor (eg ramipril 2.5mg) and consider a beta blocker (eg bisoprolol 2.5mg). Repeat LVEF within 3 weeks and if not within 10% from baseline withhold treatment. Discuss with consultant and refer to cardiology
< 40%	Withhold. If BP and renal function adequate start an ACE inhibitor (eg ramipril 2.5mg) and consider a beta blocker (eg bisoprolol 2.5mg). Repeat LVEF within 3 weeks and if < 40% withhold treatment and discuss with consultant. Refer to cardiology
Symptomatic congestive heart failure	Discontinue

Any other grade 3 or 4 toxicity- discuss with consultant.

**Adverse effects** - for full details consult product literature/ reference texts

- **Serious side effects**

Myelosuppression  
Anaphylaxis  
Teratogenicity  
Infertility/Early menopause  
Cardiotoxicity  
Peripheral neuropathy  
Interstitial lung disease  
Other primary cancer

- **Frequently occurring side effects**

Diarrhoea  
Constipation  
Fatigue  
Nausea and vomiting  
Myelosuppression  
Stomatitis and mucositis  
Arthralgia and myalgia  
Alopecia

- **Other side effects**

Fluid retention  
Red urine (for 24 hours post epirubicin)  
Deranged liver function  
Phlebitis  
Skin toxicity  
Nail changes  
Taste disturbances  
Bladder irritation

**Significant drug interactions** – for full details consult product literature/ reference texts

**Warfarin/coumarin anticoagulants:** increased or fluctuating anticoagulant effects. Avoid if possible, consider switching patient to a low molecular weight heparin during treatment or if the patient continues taking an oral anticoagulant monitor the INR at least once a week and adjust dose accordingly.

**Phenytoin:** requires close monitoring if using concurrently.

**Co-trimoxazole/trimethoprim:** enhances antifolate effect. Avoid if possible, if essential, monitor FBC regularly.

**Cyclophosphamide:**

**Amiodarone:** increased risk of pulmonary fibrosis – avoid if possible

**Clozapine:** increased risk of agranulocytosis – avoid concomitant use

**Digoxin tablets:** reduced absorption – give as liquid form

**Indapamide:** prolonged leucopenia is possible - avoid

**Itraconazole:** may increase adverse effects of cyclophosphamide

**Grapefruit juice:** decreased or delayed activation of cyclophosphamide. Patients should be advised to avoid grapefruit juice for 48 hours before and on day of cyclophosphamide dose.

**Docetaxel:**

**CYP3A4 Enzyme inducers/inhibitors:** in vitro studies suggest that CYP3A inhibitors (such as ketoconazole, ritonavir, clarithromycin and erythromycin) may raise docetaxel levels, whereas CYP3A inducers (such as rifampicin and barbiturates) may reduce docetaxel levels.

There is no data regarding drug interactions with trastuzumab or pertuzumab.

## Additional comments

Epirubicin has a lifetime maximum cumulative dose of 900mg/m<sup>2</sup>

Women of childbearing potential should use effective contraception while receiving treatment and for 6 months at least 6 months after completion.

---

## References

- National Institute for Health and Clinical Excellence. TA569 accessed 28<sup>th</sup> April 2022 via [www.nice.org.uk](http://www.nice.org.uk)
- Summary of Product Characteristics Epirubicin (Accord) accessed 28<sup>th</sup> April 2022 via [www.medicines.org.uk](http://www.medicines.org.uk)
- Summary of Product Characteristics Cyclophosphamide (Sandoz) accessed 28<sup>th</sup> April 2022 via [www.medicines.org.uk](http://www.medicines.org.uk)
- Summary of Product Characteristics Docetaxel (Accord) accessed 28<sup>th</sup> April 2022 via [www.medicines.org.uk](http://www.medicines.org.uk)
- Summary of Product Characteristics Trastuzumab ® (Roche) accessed 28<sup>th</sup> April 2022 via [www.medicines.org.uk](http://www.medicines.org.uk)
- Summary of Product Characteristics Pertuzumab (Roche) accessed 28<sup>th</sup> April 2022 via [www.medicines.org.uk](http://www.medicines.org.uk)
- Summary of Product Characteristics Phesgo ® (Roche) accessed 28<sup>th</sup> April 2022 via [www.medicines.org.uk](http://www.medicines.org.uk)
- Gunter von Minckwitz et al, Adjuvant Pertuzumab and Trastuzumab in Early HER 2 positive breast cancer. N Engl J Med 2017; 377:122-131.

---

Written/reviewed by: Based on FEC-TPH SWSCN protocol written by: Professor M Beresford (Consultant Oncologist, RUH Bath NHS Trust), Dr R Bowen (Consultant Oncologist, RUH Bath NHS Trust)

Checked by: Kate Gregory (Lead Pharmacist for SACT protocols, SWAG Cancer Alliance)

Authorised by: Dr J Braybrooke (Consultant Oncologist, UHBW NHS Trust and SWAG Cancer Alliance)

Date: April 2022

---